An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

Pfizer paid a whopping $1 billion upfront for rights to vepdegestrant (formerly ARV-4710 in 2021 – consisting of $650 million ...

Arvinas and Pfizer's drug vepdegestrant reduced the risk of tumor progression 40% compared to standard treatment for an ...

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

The drug, vepdegestrant, failed to meaningfully delay cancer progression for all patients enrolled in the study but met its ...

Arvinas/Pfizer's vepdegestrant shows efficacy in mutated breast cancer patients but not in broader population, failing to ...

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

Pfizer (NYSE:PFE) is currently dealing with shareholder proposals concerning governance issues such as religious ...